|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
WHO007761600 |
| 003 |
DE-627 |
| 005 |
20230425173159.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210720s2021 xx |||||o 00| ||eng c |
| 035 |
|
|
|a (DE-627)WHO007761600
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)JPRN-jRCT2021210012
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a COVID-19_HLH94 clinical trial
|b A phase II clinical trial with HLH-94 protocol, etoposide plus corticosteroid combination therapy, for severe illness patients with COVID-19
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 14-06-2021, Last updated: 2022-11-24
|
| 650 |
|
4 |
|a Medical Condition: severe illness patients with COVID-19 COVID-19, acute respiratory distress syndrome (ARDS) , critical care, macrophage activation syndrome (MAS) , hemophagocytic lymphohitiocytosis (HLH) , etoposide, corticosteroid, HLH-94 protocol
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Recruitment Status: Recruiting
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2021) vom: 12. Juli
|
| 773 |
1 |
8 |
|g year:2021
|g day:12
|g month:07
|
| 856 |
4 |
0 |
|u https://jrct.niph.go.jp/latest-detail/jRCT2021210012
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2021
|b 12
|c 07
|
Klinische Studie